This subgroup analysis assessing secondary prophylaxis for Pneumocystis carinii pneumonia (PCP) describes a multicenter, open-labeled, randomized, controlled trial evaluating the discontinuation of PCP prophylaxis. The main inclusion criterion was a history of PCP and an increase in the CD4 cell count to >200 cells/microL associated with receipt of highly active antiretroviral therapy for >or=3 months. The primary end point was the development of definitive or presumptive PCP. A total of 146 patients were enrolled (77 in the treatment discontinuation arm). After >2 years, 1 definitive and 1 presumptive case of PCP were observed, both of which occurred in patients who discontinued therapy. In most patients, secondary prophylaxis for PCP can be safely discontinued after potent antiretroviral therapy is initiated, but the threshold of >200 CD4 cells/microL may not be considered absolutely safe. Patients who present with symptoms after discontinuation of secondary prophylaxis should be evaluated for PCP despite high CD4 count and complete virus suppression.

Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: A randomized trial by the CIOP Study Group / Mussini, Cristina; Pezzotti, P; Antinori, A; Borghi, V; Monforte, A; Govoni, A; De Luca, A; Ammassari, A; Mongiardo, N; Cerri, Mc; Bedini, Andrea; Beltrami, C; Ursitti, Ma; Bini, T; Cossarizza, Andrea; Esposito, R.. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 36:5(2003), pp. 645-651. [10.1086/367659]

Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: A randomized trial by the CIOP Study Group

MUSSINI, Cristina;BEDINI, Andrea;COSSARIZZA, Andrea;
2003

Abstract

This subgroup analysis assessing secondary prophylaxis for Pneumocystis carinii pneumonia (PCP) describes a multicenter, open-labeled, randomized, controlled trial evaluating the discontinuation of PCP prophylaxis. The main inclusion criterion was a history of PCP and an increase in the CD4 cell count to >200 cells/microL associated with receipt of highly active antiretroviral therapy for >or=3 months. The primary end point was the development of definitive or presumptive PCP. A total of 146 patients were enrolled (77 in the treatment discontinuation arm). After >2 years, 1 definitive and 1 presumptive case of PCP were observed, both of which occurred in patients who discontinued therapy. In most patients, secondary prophylaxis for PCP can be safely discontinued after potent antiretroviral therapy is initiated, but the threshold of >200 CD4 cells/microL may not be considered absolutely safe. Patients who present with symptoms after discontinuation of secondary prophylaxis should be evaluated for PCP despite high CD4 count and complete virus suppression.
2003
36
5
645
651
Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: A randomized trial by the CIOP Study Group / Mussini, Cristina; Pezzotti, P; Antinori, A; Borghi, V; Monforte, A; Govoni, A; De Luca, A; Ammassari, A; Mongiardo, N; Cerri, Mc; Bedini, Andrea; Beltrami, C; Ursitti, Ma; Bini, T; Cossarizza, Andrea; Esposito, R.. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 36:5(2003), pp. 645-651. [10.1086/367659]
Mussini, Cristina; Pezzotti, P; Antinori, A; Borghi, V; Monforte, A; Govoni, A; De Luca, A; Ammassari, A; Mongiardo, N; Cerri, Mc; Bedini, Andrea; Beltrami, C; Ursitti, Ma; Bini, T; Cossarizza, Andrea; Esposito, R.
File in questo prodotto:
File Dimensione Formato  
2003 CID - Mussini.pdf

Accesso riservato

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 108.07 kB
Formato Adobe PDF
108.07 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/837096
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 26
social impact